Amit Noheria

Dr. Amit Noheria


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2011 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
FMFreddy DEL Carpio Munoz
Freddy DEL Carpio Munoz
FSFaisal F. Syed
Faisal F. Syed
ANAmit Noheria
Amit Noheria
YCYong-Mei Cha
Yong-Mei Cha
PFPaul A. Friedman
Paul A. Friedman
SASamuel J. Asirvatham
Samuel J. Asirvatham

24 March 2008 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
ANAmit Noheria
Amit Noheria
AKAbhishek Kumar
Abhishek Kumar
JWJohn V. Wylie
John V. Wylie
MJMark E. Josephson
Mark E. Josephson
Review from JAMA Internal Medicine — Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation — A Systematic Review

1 April 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TCTarun Chakravarty
Tarun Chakravarty
EBEric Van Belle
Eric Van Belle
HJHasan Jilaihawi
Hasan Jilaihawi
ANAmit Noheria
Amit Noheria
Luca TestaLuca Testa
Luca Testa
RMRaj R. Makkar
Raj R. Makkar

15 December 2010 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
AGApoor S. Gami
Apoor S. Gami
ANAmit Noheria
Amit Noheria
NLNirusha Lachman
Nirusha Lachman
WEWilliam D. Edwards
William D. Edwards
PFPaul A. Friedman
Paul A. Friedman
SASamuel J. Asirvatham
Samuel J. Asirvatham

1 December 2015 in Circulation
Verified
Journal Article
Closed access
ADAbhishek Deshmukh
Abhishek Deshmukh
NPNileshkumar Patel
Nileshkumar Patel
PNPeter A. Noseworthy
Peter A. Noseworthy
APAchint A. Patel
Achint A. Patel
NPNilay Patel
Nilay Patel
JVJuan F. Viles-Gonzalez
Juan F. Viles-Gonzalez
Background—: Transvenous lead removal (TLR) has made significant progress with respect to innovation, efficacy, and safety. However, limited data exist regarding trends in use and adverse outcomes outside the centers of considerable experience for TLR. The aim of our study was to examine use patterns, frequency of adverse events, and influence of hospital volume on complications. Methods and Results—: Using the Nationwide Inpatient Sample, we identified 91 890 TLR procedures. We investigated common complications including pericardial complications (hemopericardium, cardiac tamponade, or pericardiocentesis), pneumothorax, stroke, vascular complications (consisting of hemorrhage/hematoma, incidents requiring surgical repair, and accidental arterial puncture), and in-hospital deaths described with TLR, defining them by the validated International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code. We specifically assessed in-hospital death (2.2%), hemorrhage requiring transfusion (2.6%), vascular complications (2.0%), pericardial complications (1.4%), open heart surgery (0.2%), and postoperative respiratory failure (2.4%). Independent predictors of complications were female sex and device infections. Hospital volume was not independently associated with higher complications. There was a significant rise in overall complication rates over the study period. Conclusions—: The overall complication rate in patients undergoing TLR was higher than previously reported. Female sex and device infections are associated with higher complications. Hospital volume was not associated with higher complication rates. The number of adverse events in the literature likely underestimates the actual number of complications associated with TLR.

24 September 2013 in Circulation
Verified
Journal Article
Closed access
CDChristopher V. DeSimone
Christopher V. DeSimone
PFPaul A. Friedman
Paul A. Friedman
ANAmit Noheria
Amit Noheria
NPNikhil A. Patel
Nikhil A. Patel
DDDaniel C. DeSimone
Daniel C. DeSimone
SASamuel J. Asirvatham
Samuel J. Asirvatham
Background—: A patent foramen ovale (PFO) may permit arterial embolization of thrombi that accumulate on the leads of cardiac implantable electronic devices in the right-sided cardiac chambers. We sought to determine whether a PFO increases the risk of stroke/transient ischemic attack (TIA) in patients with endocardial leads. Methods and Results—: We retrospectively evaluated all patients who had endocardial leads implanted between January 1, 2000, and October 25, 2010, at Mayo Clinic Rochester. Echocardiography was used to establish definite PFO and non-PFO cohorts. The primary end point of stroke/TIA consistent with a cardioembolic etiology and the secondary end point of mortality during postimplantation follow-up were compared in PFO versus non-PFO patients with the use of Cox proportional hazards models. We analyzed 6075 patients (364 with PFO) followed for a mean 4.7±3.1 years. The primary end point of stroke/TIA was met in 30/364 (8.2%) PFO versus 117/5711 (2.0%) non-PFO patients (hazard ratio, 3.49; 95% confidence interval, 2.33–5.25; P <0.0001). The association of PFO with stroke/TIA remained significant after multivariable adjustment for age, sex, history of stroke/TIA, atrial fibrillation, and baseline aspirin/warfarin use (hazard ratio, 3.30; 95% confidence interval, 2.19–4.96; P <0.0001). There was no significant difference in all-cause mortality between PFO and non-PFO patients (hazard ratio, 0.91; 95% confidence interval, 0.77–1.07; P =0.25). Conclusions—: In patients with endocardial leads, the presence of a PFO on routine echocardiography is associated with a substantially increased risk of embolic stroke/TIA. This finding suggests a role of screening for PFOs in patients who require cardiac implantable electronic devices; if a PFO is detected, PFO closure, anticoagulation, or nonvascular lead placement may be considered.